Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 6/20 | 0.67 |
| ▸ | MAPT | P10636 | 6/20 | 0.67 |
| ▸ | NPC1 | O15118 | 5/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.67 |
| ▸ | LMNA | P02545 | 2/20 | 0.67 |
| ▸ | MEN1 | O00255 | 6/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.45 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.45 |
| ▸ | RELA | Q04206 | 2/20 | 0.45 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2655836 | 1.00 | RAB9A (0.67) | RAB9AMAPTNPC1SMN1; SMN2LMNA | |
| SCHEMBL23748560 | 0.84 | CCNB2 (0.52) | RAB9AMAPTNPC1SMN1; SMN2LMNA | |
| SCHEMBL10960804 | 0.83 | MEN1 (0.49) | RAB9AMAPTNPC1SMN1; SMN2LMNA | |
| SCHEMBL15013285 | 0.82 | MAPT (0.55) | MAPTNPC1MEN1KMT2AL3MBTL1 | |
| SCHEMBL28863987 | 0.80 | RAB9A (0.77) | RAB9AMAPTNPC1SMN1; SMN2LMNA | |
| SCHEMBL30318898 | 0.78 | HPD (0.49) | MAPTMEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL1121791 | 0.78 | HPD (0.49) | MAPTMEN1KMT2AL3MBTL1ALDH1A1 | |
| SCHEMBL10535540 | 0.78 | CCNB2 (0.46) | RAB9AMAPTNPC1SMN1; SMN2LMNA | |
| SCHEMBL10535536 | 0.78 | CCNB2 (0.46) | RAB9AMAPTNPC1SMN1; SMN2LMNA | |
| SCHEMBL2986814 | 0.77 | HPD (0.57) | MEN1KMT2AALDH1A1HPDPTGER1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110301155-A1 | INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-08 | — | — | US | disclosed |
| US-20110301155-A1 | INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-08 | — | — | US | disclosed |
| US-20110301155-A1 | INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-12-08 | — | — | US | disclosed |
| EP-2157859-A1 | INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE | Takeda Pharmaceutical Company Limited (JP) | 2010-03-03 | — | — | EP | disclosed |
| WO-2008156757-A1 | INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008156757-A1 | INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-12-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110301155-A1 | INDAZOLE COMPOUNDS FOR ACTIVATING GLUCOKINASE | GCKR, GCK, KHK | RAB9A 4253/4885MAPT 4750/4885NPC1 3545/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.